Cancer Cell Biology
Free Access
Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation
Fax: +468‐5858‐1020.
Abstract
Endogenous and synthetic cannabinoids exert antiproliferative and proapoptotic effects in various types of cancer and in mantle cell lymphoma (MCL). In this study, we evaluated the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) in non‐Hodgkin lymphomas of B cell type (n = 62). A majority of the lymphomas expressed higher mRNA levels of CB1 and/or CB2 as compared to reactive lymphoid tissue. With the exception of MCL, which uniformly overexpresses both CB1 and CB2, the levels of cannabinoid receptors within other lymphoma entities were highly variable, ranging from 0.1 to 224 times the expression in reactive lymph nodes. Low levels of the splice variant CB1a, previously shown to have a different affinity for cannabinoids than CB1, were detected in 44% of the lymphomas, while CB1b expression was not detected. In functional studies using MCL, Burkitt lymphoma (BL), chronic lymphatic leukemia (CLL) and plasma cell leukemia cell lines, the stable anandamide analog R(+)‐methanandamide (R(+)‐MA) induced cell death only in MCL and CLL cells, which overexpressed both cannabinoid receptors, but not in BL. In vivo treatment with R(+)‐MA caused a significant reduction of tumor size and mitotic index in mice xenografted with human MCL. Together, our results suggest that therapies using cannabinoid receptor ligands will have efficiency in reducing tumor burden in malignant lymphoma overexpressing CB1 and CB2. © 2008 Wiley‐Liss, Inc.
Citing Literature
Number of times cited: 25
- Lucas M. Bryant, Kelly E. Daniels, David M. Cognetti, Patrick Tassone, Adam J. Luginbuhl and Joseph M. Curry, Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients, Laryngoscope Investigative Otolaryngology, 3, 3, (169-177), (2018).
- Adrienne Nugent and Richard L. Proia, The role of G protein-coupled receptors in lymphoid malignancies, Cellular Signalling, 10.1016/j.cellsig.2017.08.002, 39, (95-107), (2017).
- Ana Inés Salazar, Claudia Vercelli, Victoria Schiariti, Carlos Davio, Fernando Correa and Ana María Franchi, Heparin exerts anti-apoptotic effects on uterine explants by targeting the endocannabinoid system, Apoptosis, 21, 9, (965), (2016).
- Guillermo Velasco, Sonia Hernández-Tiedra, David Dávila and Mar Lorente, The use of cannabinoids as anticancer agents, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, (259), (2016).
- Jianfeng Wang, Yunze Xu, Yun Zou, Liangsong Zhu, Baijun Dong, Jiwei Huang, Yonghui Chen, Wei Xue, Yiran Huang, Wen Kong and Jin Zhang, Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression, Tumor Biology, 37, 12, (16237), (2016).
- Patricia Freund, Edit A. Porpaczy, Trang Le, Michaela Gruber, Clemens Pausz, Philipp Staber, Ulrich Jäger, Katrina Vanura and Guillermo Velasco, Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation, PLOS ONE, 11, 6, (e0156693), (2016).
- Valeria Gasperi, Daniela Evangelista, Isabella Savini, Domenico Del Principe, Luciana Avigliano, Mauro Maccarrone and Maria Valeria Catani, Downstream effects of endocannabinoid on blood cells: implications for health and disease, Cellular and Molecular Life Sciences, 10.1007/s00018-015-1924-0, 72, 17, (3235-3252), (2015).
- Michael E. Williams, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas E. Witzig and Leo I. Gordon, Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop, Leukemia & Lymphoma, 54, 9, (1882), (2013).
- Simona Pisanti, Paola Picardi, Alba D’Alessandro, Chiara Laezza and Maurizio Bifulco, The endocannabinoid signaling system in cancer, Trends in Pharmacological Sciences, 10.1016/j.tips.2013.03.003, 34, 5, (273-282), (2013).
- Barbara L.F. Kaplan, The role of CB1 in immune modulation by cannabinoids, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2012.12.004, 137, 3, (365-374), (2013).
- Iain Brown, Maria G. Cascio, Dino Rotondo, Roger G. Pertwee, Steven D. Heys and Klaus W.J. Wahle, Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators, Progress in Lipid Research, 10.1016/j.plipres.2012.10.001, 52, 1, (80-109), (2013).
- Amina M. Bagher, Robert B. Laprairie, Melanie E.M. Kelly and Eileen M. Denovan-Wright, Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes, European Journal of Pharmacology, 721, 1-3, (341), (2013).
- RB Laprairie, MEM Kelly and EM Denovan‐Wright, The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription, British Journal of Pharmacology, 167, 8, (1583-1595), (2012).
- Daniel W. Bowles, Cindy L. O’Bryant, D. Ross Camidge and Antonio Jimeno, The intersection between cannabis and cancer in the United States, Critical Reviews in Oncology/Hematology, 83, 1, (1), (2012).
- Béla Horváth, Partha Mukhopadhyay, Malek Kechrid, Vivek Patel, Galin Tanchian, David A. Wink, Jürg Gertsch and Pál Pacher, β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2012.01.014, 52, 8, (1325-1333), (2012).
- Clementina Manera, Giuseppe Saccomanni, Anna Maria Malfitano, Simone Bertini, Francesca Castelli, Chiara Laezza, Alessia Ligresti, Valentina Lucchesi, Tiziano Tuccinardi, Flavio Rizzolio, Maurizio Bifulco, Vincenzo Di Marzo, Antonio Giordano, Marco Macchia and Adriano Martinelli, Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold, European Journal of Medicinal Chemistry, 52, (284), (2012).
- Nazik Rayman, King H. Lam, Bronno van der Holt, Clara Koss, Joost van Leeuwen, Leo M. Budel, Andries H. Mulder, Pieter Sonneveld and Ruud Delwel, The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B‐cell lymphomas, European Journal of Haematology, 86, 6, (466-476), (2011).
- Anna Maria Malfitano, Elena Ciaglia, Giuseppina Gangemi, Patrizia Gazzerro, Chiara Laezza and Maurizio Bifulco, Update on the endocannabinoid system as an anticancer target, Expert Opinion on Therapeutic Targets, 10.1517/14728222.2011.553606, 15, 3, (297-308), (2011).
- Agata M. Wasik, Birger Christensson and Birgitta Sander, The role of cannabinoid receptors and the endocannabinoid system in mantle cell lymphoma and other non-Hodgkin lymphomas, Seminars in Cancer Biology, 21, 5, (313), (2011).
- A M Wasik, S Almestrand, X Wang, K Hultenby, Å-L Dackland, P Andersson, E Kimby, B Christensson and B Sander, WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells, Cell Death & Disease, 2, 11, (e225), (2011).
- Aymen I. Idris and Stuart H. Ralston, Cannabinoids and Bone: Friend or Foe?, Calcified Tissue International, 87, 4, (285), (2010).
- Roger G Pertwee, Emerging strategies for exploiting cannabinoid receptor agonists as medicines, British Journal of Pharmacology, 156, 3, (397-411), (2009).
- Nele Evens, Giulio G. Muccioli, Nele Houbrechts, Didier M. Lambert, Alfons M. Verbruggen, Koen Van Laere and Guy M. Bormans, Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging, Nuclear Medicine and Biology, 36, 4, (455), (2009).
- Sumner Burstein and Rebecca Salmonsen, Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation, Bioorganic & Medicinal Chemistry, 16, 22, (9644), (2008).
- Stefan Almestrand, Xiao Wang, Åsa Jeppsson-Ahlberg, Marcus Nordgren, Jenny Flygare, Birger Christensson, Stephan Rössner and Birgitta Sander, Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling, PeerJ, 10.7717/peerj.1056, 3, (e1056), (2015).
